Just in: $PLTR posts a double beat, with very strong guidance. 🥳🎉
Adjusted EPS 21c, est. 17c ✅
Revenue $1.18b, est. $1.09b ✅
Adjusted EBITDA $606.5m, est. $502.1m ✅
US commercial revenue +121% y/y to $397m 🔥
Sees FY revenue $4.40b to $4.40b, saw $4.14b to $4.15b 🔥
Sees FY adjusted operating profit $2.15b to $2.16b, est. $1.93b 🔥
Sees FY US commercial revenue above $1.43b 🔥
Sees Q4 revenue $1.33b, est. $1.19b 🔥
$PLTR's revenue growth is in a class of its own, accelerating to 114% in Q3 2025 from 94% in Q2
The company highlights extremely impressive commercial growth. For many investors years ago this was the crucial concern. Can they grow in the commercial space?
The company is proving that not only can they grow, but they can grow much faster than their government segment.
Short interest in $IREN is rising as the stock price surges.
Some hedge funds are apparently increasingly confident that this company is a dud.
Time will tell who's right, but most of the time you see short covering into a surge.
Meanwhile, $IREN call buyers are targeting $70 as the area of largest interest in upside. That creates a potential area of resistance, or a "call wall" around that level.
We also have a large area of put-derived support around $61 given the interest at that level.
Implied volatility on the $IREN options chain is leaning bullish, but nowhere near the extremes we have seen when it was very lopsided. Meaning we could get a push to that $70 call wall as the next move up in this stock as options buyers continue to influence price discovery.
I'm hearing a fair number of people believe they're owed money that may or may not be paid out by FTT. Which has been a growing concern over the last week or longer.
Be careful with these firms, folks.
You never know what may end up happening to what they promise to you.
Hedge funds were on a buying spree last week in health care, financials, industrials and tech, per Goldman
Most of the buying of US equity exposure was within single stocks vs indices and ETFs last week by hedge funds, according to Goldman prime data.
Last week healthcare stocks saw the largest inflows from hedge funds in over a year, according to data from Goldman. This was also the third straight week of buying.
44% of small cap companies are unprofitable vs 19% of midcaps and just 7% of large caps.
This is one reason that there's no reason for a rotation into small caps. The value really isn't there.
One of the catalysts for $IWM's surge was a record amount of retail call buying. This is not how rotations tend to look. Instead, this appeared to have been speculative excess chasing momentum.
Another driver of the $IWM rally was significant de-grossing by hedge funds, who favored the Russell 2000 as a macro short to offset concentrated positioning in mega caps and $NDX.